Clinical Trial Update: Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)

View source ↗

Summary

A completed clinical trial examined Ventavis (iloprost) inhalation behavior using the I-Neb AAD system in patients with pulmonary arterial hypertension when swi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ventavis (iloprost)

Snippet

Sponsor: Bayer | Conditions: Hypertension, Pulmonary | Status: COMPLETED